RingelMD, SosaJA, BalochZ, et al.2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer. Thyroid, 2025; 35(8):841–985; doi: 10.1177/10507256251363120
2.
HaugenBR, AlexanderEK, BibleKC, et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016; 26(1):1–133; doi: 10.1089/thy.2015.0020
3.
PrawSS, GigliottiBJ, TessnowA, et al.Executive summary of the 2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer. Thyroid, 2025; 35(11):1214–1220; doi: 10.1177/10507256251390877
4.
MallickU, HarmerC, YapB, et al.Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med, 2012; 366(18):1674–1685; doi: 10.1056/NEJMoa1109589
5.
SchlumbergerM, CatargiB, BorgetI, et al.; Tumeurs de la Thyroïde Refractaires Network for the Essai Stimulation Ablation Equivalence Trial. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med, 2012; 366(18):1663–1673; doi: 10.1056/NEJMoa1108586
6.
TuttleRM, AhujaS, AvramAM, et al.Controversies, consensus, and collaboration in the use of (131)I therapy in differentiated thyroid cancer: A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid, 2019; 29(4):461–470; doi: 10.1089/thy.2018.0597
7.
GulecSA, AhujaS, AvramAM, et al.A joint statement from the American thyroid association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on current diagnostic and theranostic approaches in the management of thyroid cancer. Thyroid, 2021; 31(7):1009–1019; doi: 10.1089/thy.2020.0826
8.
LeboulleuxS, BournaudC, ChougnetCN, et al.Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N Engl J Med, 2022; 386(10):923–932; doi: 10.1056/NEJMoa2111953
9.
LeboulleuxS, BournaudC, ChougnetCN, et al.Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial. Lancet Diabetes Endocrinol, 2025; 13(1):38–46; doi: 10.1016/S2213-8587(24)00276-6
10.
MallickU, NewboldK, BeasleyM, et al.Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): A randomised, multicentre, non-inferiority trial. Lancet, 2025; 406(10498):52–62; doi: 10.1016/S0140-6736(25)00629-4
11.
DanielsGH, KoppPA. Guidelines are not gospel!. Thyroid, 2019; 29(6):753–757; doi: 10.1089/thy.2019.0283
